ETF Managers Group LLC Has $717,000 Stake in Pfizer Inc. (NYSE:PFE)

Posted by Defense World Staff on Jun 30th, 2023

ETF Managers Group LLC trimmed its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 66.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,580 shares of the biopharmaceutical company’s stock after selling 34,977 shares during the period. ETF Managers Group LLC’s holdings in Pfizer were worth $717,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Harbor Investment Advisory LLC increased its holdings in Pfizer by 3.6% in the fourth quarter. Harbor Investment Advisory LLC now owns 23,977 shares of the biopharmaceutical company’s stock valued at $1,229,000 after purchasing an additional 825 shares during the period. BancFirst Trust & Investment Management grew its holdings in Pfizer by 2.3% during the 1st quarter. BancFirst Trust & Investment Management now owns 17,794 shares of the biopharmaceutical company’s stock worth $719,000 after acquiring an additional 398 shares during the period. Secure Asset Management LLC grew its holdings in Pfizer by 3.5% during the 4th quarter. Secure Asset Management LLC now owns 15,835 shares of the biopharmaceutical company’s stock worth $811,000 after acquiring an additional 537 shares during the period. Range Financial Group LLC grew its holdings in Pfizer by 2.8% during the 1st quarter. Range Financial Group LLC now owns 37,010 shares of the biopharmaceutical company’s stock worth $1,510,000 after acquiring an additional 1,024 shares during the period. Finally, Allred Capital Management LLC grew its holdings in Pfizer by 1.9% during the 4th quarter. Allred Capital Management LLC now owns 20,425 shares of the biopharmaceutical company’s stock worth $1,047,000 after acquiring an additional 387 shares during the period. 67.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb acquired 1,000 shares of the firm’s stock in a transaction on Monday, May 8th. The shares were purchased at an average price of $38.58 per share, for a total transaction of $38,580.00. Following the completion of the transaction, the director now owns 6,000 shares of the company’s stock, valued at $231,480. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.05% of the company’s stock.

Pfizer Price Performance

Shares of NYSE PFE opened at $36.13 on Friday. Pfizer Inc. has a fifty-two week low of $35.76 and a fifty-two week high of $54.93. The stock has a market cap of $203.94 billion, a price-to-earnings ratio of 7.11, a PEG ratio of 1.20 and a beta of 0.64. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.11 and a current ratio of 1.37. The firm’s 50-day simple moving average is $38.39 and its 200 day simple moving average is $42.32.

Pfizer (NYSE:PFE – Free Report) last posted its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.00 by $0.23. The firm had revenue of $18.28 billion during the quarter, compared to analyst estimates of $16.49 billion. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. The company’s revenue for the quarter was down 28.8% on a year-over-year basis. During the same quarter last year, the business posted $1.62 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 3.35 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 5th. Shareholders of record on Friday, July 28th will be paid a $0.41 dividend. The ex-dividend date of this dividend is Thursday, July 27th. This represents a $1.64 annualized dividend and a yield of 4.54%. Pfizer’s dividend payout ratio (DPR) is 32.28%.

Analyst Ratings Changes

A number of analysts have weighed in on PFE shares. Jefferies Financial Group started coverage on Pfizer in a report on Monday, March 6th. They set a “hold” rating and a $43.00 price target for the company. StockNews.com initiated coverage on shares of Pfizer in a research report on Thursday, May 18th. They set a “buy” rating on the stock. Barclays cut their price objective on shares of Pfizer from $43.00 to $40.00 in a research report on Wednesday, May 3rd. Wells Fargo & Company cut their price objective on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Friday, March 17th. Finally, Morgan Stanley cut their price objective on shares of Pfizer from $45.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Monday, April 10th. Ten analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $46.67.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.